TELO
Telomir Pharmaceuticals, Inc.
1.20$
+2.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -10.2% | -26.6% | -40.0% | -50.4% | +27.1% | -62.9% | +68.9% | +792.2% | -0.8% | -21.1% | -7.3% | |
| – | +84.2% | +704.9% | -40.0% | -50.4% | +27.1% | -62.9% | +68.9% | +792.2% | -0.8% | -21.1% | -7.3% | |
| – | -49.8% | +265,888.1% | -42.5% | -55.7% | +51.7% | -68.2% | +87.2% | +871.6% | -0.6% | -23.7% | -7.0% | |
| – | -49.8% | +265,888.1% | -42.5% | -55.7% | +51.7% | -68.2% | +87.2% | +871.6% | -0.6% | -23.7% | -7.0% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | – | – | – | – | – | – | – | |
| – | +194.8% | – | – | – | – | – | – | – | – | – | – | |
| – | -57.5% | -63.6% | +9.8% | +12.3% | +13.5% | -4.2% | -46.6% | +21.4% | +237.7% | -42.1% | -59.8% | |
| – | -57.5% | -63.6% | +9.8% | +12.3% | +13.5% | -4.2% | -46.6% | +21.4% | +237.7% | -42.1% | -59.8% | |
| – | -92.5% | -92.2% | – | – | +0.0% | +0.0% | +0.0% | +0.0% | +407.1% | -57.2% | – | |
| – | +42.6% | -68.7% | +77.7% | +28.6% | +16.0% | -4.9% | -54.4% | +29.2% | +63.0% | -47.9% | -30.1% | |
| – | +57.9% | -12.3% | -48.0% | -71.8% | +45.5% | -125.1% | – | +1,350.3% | -15.3% | -16.1% | +1.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -1.1% | +1.1% | +0.0% | -0.2% | +0.8% | +0.8% | +3.4% | +10.8% | +0.0% | +0.0% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.